Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 907048 | ISIN: FR0000035370 | Ticker-Symbol: 1DJ
Frankfurt
28.03.24
15:29 Uhr
13,940 Euro
-0,100
-0,71 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BASTIDE LE CONFORT MEDICAL SA Chart 1 Jahr
5-Tage-Chart
BASTIDE LE CONFORT MEDICAL SA 5-Tage-Chart
RealtimeGeldBriefZeit
13,94014,28028.03.

Aktuelle News zur BASTIDE LE CONFORT MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.BASTIDE: 2023-2024 half-yearly results: Organic growth up 5.7%, EBITDA up 7.5%, Increase in recurring operating profit despite the inflationary context and margin of 8.3%. 2023-2024 outlook confirmed186Caissargues, March 20, 2024 In € millions - Year ended June 30 H1 2022-2023 H1 2023-2024 Change Revenue 249.7 265.0 +6.1 % EBITDA* 49.9 53.6 +7.5 % EBITDA...
► Artikel lesen
15.02.BASTIDE: Organic growth accelerated to 6.1% in second-quarter 2023-2024 and confirmation of 2023-2024 adjusted targets578Caissargues, February 15, 2024 In €m 2022-2023 2023-2024 Organic growth Published growth Q1 revenue 119.5 127.9 +5.2% +7.0% Q2 revenue 129.9 137.1 +6.1% +5.5% H1...
► Artikel lesen
04.12.23BASTIDE: Strategic sale of e-commerce subsidiary Distrimed294Caissargues, December 4, 2023 Groupe Bastide announced today the sale of its Distrimed subsidiary to Hygie31, a European specialist in consulting and support for healthcare networks, majority-owned...
► Artikel lesen
16.11.23BASTIDE: Dynamic 7% growth in first-quarter 2023-2024 / 2023-2024 targets confirmed336Caissargues, November 16, 2023 In € millions 2022-2023 published 2022-2023* restated 2023-2024 published Change First-quarter revenue (at September 30) 122.0 119.5 127.9 +7.0% ...
► Artikel lesen
19.10.23BASTIDE: Groupe Bastide announces its 2023-2024 financial calendar343Caissargues, October 19, 2023 Events Dates* 2023-2024 Q1 Revenue Thursday November 16, 2023 2023-2024 H1 Revenue Thursday February 15, 2024 2023-2024 H1 Results Wednesday...
► Artikel lesen
18.10.23BASTIDE: 2022-2023 annual results: Record EBITDA of over EUR 100 million, Recurring operating margin of 8.4%, exceeding the target, Operating free cash flow of EUR 39 million // 2023-2024 outlook: sustained growth and a focus on reducing debt326Caissargues, October 18, 2023 In € millions - Year ended June 30 2021-2022 2022-2023 Change Revenue 468.3 508.0 +8.5% EBITDA[1] 95.0 101.6 +5.6% EBITDA...
► Artikel lesen
30.08.23BASTIDE: Annual revenue of EUR 508 million, growth of 11.0%, in line with the target // 2022-2023 profitability targets confirmed402Caissargues, August 30, 2023 In € millions 2021-2022 published 2021-2022* restated 2022-2023 published Change Fourth-quarter revenue 126.9 123.4 127.9 +3.6% Annual...
► Artikel lesen
06.07.23BASTIDE: Groupe Bastide strengthens its position in home healthcare services in France and expands into the Netherlands467Caissargues, July 6, 2023 Groupe Bastide announced today that it has finalized two small acquisitions, one strengthening its Perfusion business in France and the other extending the Group's geographic...
► Artikel lesen
30.06.23BASTIDE: Changes in Group's Executive Management following the departure of Jean-Claude Brdenk591Caissargues, June 30, 2023 Bastide Group today announces the departure of Jean-Claude Brdenk, Deputy CEO in charge of operations, who has resigned from his position for personal reasons, with...
► Artikel lesen
10.05.23BASTIDE: Organic growth accelerated to 9.1% in third-quarter 2022-2023 // 2022-2023 targets confirmed377Caissargues, May 10, 2023 In € millions 2021-2022 published 2021-2022* restated 2022-2023 published Change 3rd quarter revenue 118.5 115.8 130.6 +12.8% 9-month...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1